Biotech startup Eyestem secured $6.4 million in its Series A led by Biological E. Ltd and others


Biotech startup Eyestem secured $6.4 million in its Series A led by Biological E. Ltd, Alkem, NATCO, Anurag Bagaria and Karan Bagaria from Kemwell Biopharma where existing investors–Endiya Partners and Kotak Private Equity also participated.


Eyestem plans to use the funds to further develop its cell therapy platform and conduct early clinical trials of its patented product. Eyestem's goal is to create a cell therapy platform to treat incurable diseases and to democratise global access to new technologies. Eyestem also stated that it has formed scientific innovation associations in India, the United Kingdom, and the United States, and that it has received grants from the Department of Biotechnology.

12 views0 comments